Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...
Vaccinations01:51

Vaccinations

Overview
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge and acceptability of male HPV vaccination among young people and community stakeholders in northwest Tanzania: social sciences in the Add-Vacc trial.

Vaccine·2025
Same author

Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials.

The Lancet. Respiratory medicine·2025
Same author

Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review.

Human vaccines & immunotherapeutics·2025
Same author

Evidence for an HPV one-dose schedule.

Vaccine·2024
Same author

Overview of CHIC symposia series: Summary of Africa and South Asia symposia.

Vaccine·2024
Same author

An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.

Preventive medicine reports·2023

Related Experiment Video

Updated: Jul 10, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Prophylactic HPV vaccines.

Margaret Stanley1

  • 1Department of Pathology, University of Cambridge, Cambridge, UK. mas@mole.bio.cam.ac.uk

Drugs of Today (Barcelona, Spain : 1998)
|November 8, 2007
PubMed
Summary

Human papillomavirus (HPV) L1 VLP vaccines offer significant public health benefits, preventing major cancers like cervical, vulval, and anal cancers. These vaccines also reduce genital warts and high-grade cervical abnormalities, improving overall health and well-being.

Area of Science:

  • Immunology
  • Public Health
  • Gynecologic Oncology

Background:

  • Human papillomavirus (HPV) infections are a leading cause of several cancers and genital warts.
  • Cervical cancer, vulval cancer, and anal cancer pose significant public health challenges.
  • Cervical intraepithelial neoplasia (CIN) often requires invasive procedures like LEEP and LLETZ.

Purpose of the Study:

  • To highlight the public health impact of HPV L1 VLP vaccines.
  • To outline the preventative benefits of HPV L1 VLP vaccines against various cancers and conditions.
  • To emphasize the long-term health and economic advantages of widespread HPV vaccination.

Main Methods:

  • Review of existing data on HPV vaccine efficacy and public health outcomes.
  • Analysis of projected disease reduction rates for HPV-related cancers and conditions.

Related Experiment Videos

Last Updated: Jul 10, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

  • Assessment of health economic benefits associated with HPV vaccination programs.

    • Main Results:

    • HPV L1 VLP vaccines can prevent 80% of cervical cancers, 60% of vulval cancers, and 80% of anal cancers long-term.
    • Vaccines are expected to prevent over 90% of genital warts in the short to medium term.
    • Significant reduction in high-grade CIN incidence, decreasing the need for LEEP and LLETZ procedures.

    Conclusions:

    • HPV L1 VLP vaccines represent a major advancement in public health, offering substantial disease prevention.
    • The vaccines provide significant health economic benefits alongside a major improvement in human health and well-being.
    • Widespread vaccination is crucial for maximizing the long-term benefits of HPV prevention.